Acriptega Hiv Tablets

Q1: What is Acriptega used for?

Acriptega is a triple fixed-dose combination of Dolutegravir 50mg + Lamivudine 300mg + Tenofovir Disoproxil Fumarate 300mg. It is used as a complete, once-daily single-tablet regimen (STR) for HIV-1 treatment in adults and adolescents.

Q2: How do the three components of Acriptega work?

Dolutegravir (INSTI) blocks HIV integrase from inserting viral DNA into host chromosomes. Lamivudine (NRTI) terminates reverse transcriptase synthesis as a chain terminator. Tenofovir DF (NRTI) provides a second complementary reverse transcriptase block — targeting HIV replication at two critical steps.

Q3: Why is this regimen (DTG/3TC/TDF) preferred?

This TDF-based DTG regimen has extensive clinical trial and real-world data supporting its efficacy. It is included in WHO, US DHHS, and European EACS treatment guidelines as a preferred option. It avoids the HLA-B*5701 testing requirement needed for Abacavir-based regimens.

Q4: How should Acriptega be taken?

Take one tablet once daily at a consistent time, with or without food. Take at least 2 hours before — or 6 hours after — antacids, iron supplements, or calcium-containing products, which reduce Dolutegravir absorption.

Q5: What are the most common side effects?

Insomnia and headache (from Dolutegravir) are most common. Nausea, diarrhea, and fatigue can occur early but usually improve. Neuropsychiatric effects (anxiety, mood changes) affect a minority of patients.

Q6: What kidney monitoring is required for Tenofovir DF?

Tenofovir Disoproxil Fumarate (TDF) can cause kidney tubular toxicity in some patients. Baseline and regular monitoring of serum creatinine and estimated GFR is required. Patients with pre-existing kidney disease may benefit from TAF-based alternatives.

Q7: What bone considerations apply to Tenofovir DF?

TDF is associated with modest reductions in bone mineral density. Calcium and vitamin D supplementation is often recommended. Consider baseline DXA scan for patients with osteoporosis risk factors.

Q8: Does Lamivudine in Acriptega also treat hepatitis B?

Yes. Lamivudine is active against hepatitis B virus. If you have HIV/HBV co-infection and switch away from this regimen, you must ensure continued HBV coverage to prevent HBV flares. Never stop Lamivudine in HIV/HBV co-infection without specialist guidance.

Q9: What is the resistance profile of Acriptega?

Dolutegravir's high barrier to resistance and the dual NRTI backbone make this regimen very durable. Virological failure is uncommon in adherent patients. If failure occurs, resistance testing is essential before switching regimens.

Q10: Can Acriptega be used during pregnancy?

Dolutegravir-based regimens are now recommended in pregnancy by WHO and many national guidelines. The complete antiretroviral regimen during pregnancy must be managed jointly by an HIV specialist and obstetrician.

Q11: How should Acriptega tablets be stored?

Store at room temperature away from direct light and moisture. Keep in original packaging out of reach of children. Do not use after the expiry date.

Q12: Do I need a prescription?

Yes. Acriptega is a prescription-only antiretroviral regimen requiring HIV specialist prescribing and regular viral load and renal monitoring.